Hasten
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hasten - overview
Established
2020
Location
Hefei, Anhui, China
Primary Industry
Biotechnology
About
Founded in 2020 and based in Hefei, China, Hasten is a biopharmaceutical company that focuses on the research and development of drugs in the field of chronic disease and age-related disease management. The company has offices in cities such as Beijing, Shanghai and Guangzhou. As of 2023, it has more than 700 employees. In April 2023, Hasten raised USD 315 million series B funding co-led by new investor Mubadala Capital and returning investor CBC Group.
The company relies on the healthcare platform and resources of its shareholder, Kangqiao Capital, to enrich its product mix and product pipeline in the area of chronic disease and age-related disease management. The company's main products include Adenidine, Yidabi and Basexin, etc. Its products are used in areas such as cardiovascular and metabolism. The company also provides other services including pharmaceutical commissioning, pharmaceutical wholesaling, testing and inspection services, pharmaceutical import and export, and health food production and sales.
Current Investors
CBC Group, Hefei State-Owned Assets Holding, Ruimu Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.hastenpharma.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Hasten - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.